Except for solid tumors, in AML, FTO inhibition has been reported to inhibit the expression of LILRB4, identified as an immune checkpoint gene that plays a vital role in the immunotherapy of AML, enabling AML cells to be more sensitive to T-cell toxicity and preventing immune escape, thus serving as a potential enhancer for immunotherapy of AML (157). The gene discussed is LILRB4; the disease is acute myeloid leukemia.